<p>Avadel Pharmaceuticals plc disclosed that the waiting period for regulatory review has expired regarding the planned acquisition of Avadel by Alkermes plc. This development marks the satisfaction of a key condition for the closing of the transaction. Completion of the acquisition remains subject to additional customary conditions, including approval by Avadel shareholders and final approval by the Irish High Court. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avadel Pharmaceuticals plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-119670), on December 09, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

ALKS

AVDL

<p>The regulatory waiting period for Alkermes' acquisition of Avadel Pharmaceuticals has expired, marking a key step towards closing the deal. The acquisition still requires Avadel shareholder approval and final approval by the Irish High Court.</p>

HSR Waiting Period Expires for Avadel Pharmaceuticals Acquisition by Alkermes